BioNTech (BNTX) has drawn fresh attention after recent share price moves, with the stock up around 9% over the past week and around 16% over the past month, inviting closer scrutiny from investors.

Phase 1/2a trial of BNT324/DB-1311 in solid tumors showed a 32.4% unconfirmed objective response rate and 82.4% disease control rate. BNT324/DB-1311 showed a manageable safety profile across all ...

An update from BioNTech SE ( ($BNTX) ) is now available. On January 6, 2026, BioNTech SE reported that CureVac N.V. had completed a previously ...

BioNTech SE ADR (NASDAQ:BNTX) stock is up 2.8% to trade at $825.41 at last glance, after an Evercore ISI upgrade to "outperform" from "in-line." The analyst in question also hiked its price target to ...

We have seen 119 institutional investors add shares of $BNTX stock to their portfolio, and 192 decrease their positions in their most recent quarter.

Shares of BioNTech SE – ADR (NASDAQ:BNTX) fell 5.7% to $115.84 on Monday, part of a broader decline in vaccine stocks triggered by Moderna's updated revenue guidance for 2025, which fell below analyst ...

We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against the other German stocks. In Germany, ...

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company reported earnings per share of €1.08 compared to Wall Street’s estimate of 44 ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

We have seen 128 institutional investors add shares of $BNTX stock to their portfolio, and 130 decrease their positions in their most recent quarter.